Chronic Medication Core Formulary

Total Page:16

File Type:pdf, Size:1020Kb

Chronic Medication Core Formulary CHRONIC MEDICATION CORE FORMULARY Effective 1 January 2013 • This formulary represents drugs covered for chronic use for 25 Chronic Disease List (CDL) conditions and individual Diagnosis and Treatment Pairs (DTP) conditions. • Reimbursement of medicines for non-CDL and non-DTP conditions is subject to Scheme Rules and the Metropolitan Health Risk Management Medicine Reimbursement Policy. • Unless stipulated, all active ingredients listed in this formulary are subject to the Metropolitan Health Reference Price (MetRef). • The examples below serve as a guide on the trade names available for the active ingredients listed and not for marketing a specific brand. • Any product within the MetRef category may be used, however a co-payment may be attracted if the product selected is above the generic reference threshold. • The dispensing pharmacist may make a generic substitution to assist members in avoiding a co-payment. • Treatment designated as "Accepted treatment" indicates that this is a medicine covered as first line, according to the Metropolitan Health Risk Management Medicine Reimbursement Policy. • For treatment designated as "Motivation required", certain criteria as specified in the Metropolitan Health Risk Management Medicine Reimbursement Policy should be met. • For treatment designated as "Special investigation", the relevant clinical investigation reports as specified in the Metropolitan Health Risk Management Medicine Reimbursement Policy are required. Abbreviations of dosage form CAP Capsule ENE Enema OPD Eye drops SYR Syrup CPS Capsule (Inhaler) INH Inhaler SLN Sublingual TAB Tablet CRM Cream INJ Injection SRC Slow release capsule UNG Ointment DRP Drops LOT Lotion SRT Slow release tablet DSP Dispersible NAS Nasal spray SUP Suppository ECT Enteric-coated tablet NOD Nasal drops SUS Suspension DOSAGE ACTIVE INGREDIENT STRENGTH EXAMPLE 1 EXAMPLE 2 CLASS COMMENT FORM CHRONIC DISEASE LIST CONDITIONS (CDLs) ADDISON'S DISEASE ICD10: E27.1 Fludrocortisone 0.1mg TAB Florinef acetate Corticosteroids , oral Motivation required Hydrocortisone 10mg TAB Covocort Corticosteroids , oral Accepted treatment Prednisolone 5mg TAB Capsoid Lenisolone Corticosteroids , oral Accepted treatment Prednisone 5mg TAB Be-tabs prednisone Panafcort Corticosteroids , oral Accepted treatment Page 1 of 81 DOSAGE ACTIVE INGREDIENT STRENGTH EXAMPLE 1 EXAMPLE 2 CLASS COMMENT FORM ASTHMA ICD10: J45.0, J45.1, J45.8, J45.9 Aminophylline 225mg SRT Phyllocontin Xanthines Motivation required Beclometasone 100mcg INH Beclate 100 Becotide 100 comp Corticosteroids, inhaled Accepted treatment Beclometasone 200mcg INH Beclate 200 Corticosteroids, inhaled Accepted treatment Beclometasone 50mcg INH Beclate 50 Becotide complete Corticosteroids, inhaled Accepted treatment Budeflam 300 dose gentle- Inflammide 100 mac 300 Budesonide 100mcg INH Corticosteroids, inhaled Accepted treatment haler hfa dose Budeflam 300 dose gentle- Inflammide 200 mac 300 Budesonide 200mcg INH Corticosteroids, inhaled Accepted treatment haler hfa dose Budesonide 200mcg CPS Budeflam DP Caps Inflacor 200 Corticosteroids, inhaled Accepted treatment Budesonide 100mcg CPS Inflacor 100 Corticosteroids, inhaled Accepted treatment Budesonide 400mcg CPS Inflacor 400 Corticosteroids, inhaled Accepted treatment Inflammide 400 Novolizer Budesonide 400mcg INH Corticosteroids, inhaled Accepted treatment Complete Inflammide 400 Novolizer Budesonide 400mcg INH Corticosteroids, inhaled Accepted treatment refill Symbicord turboh 120 dose Corticosteroids and beta agonists, long Budesonide and formoterol 160/4.5mcg INH Motivation required 160mcg;45mc acting Symbicord turboh 120dose Corticosteroids and beta agonists, long Budesonide and formoterol 80/4.5mcg INH Motivation required 80:4 5mcg acting Symbicord turboh 60 dose Corticosteroids and beta agonists, long Budesonide and formoterol 160/4.5mcg INH Motivation required 160mcg;45mcg acting Symbicord turboh 60dose Corticosteroids and beta agonists, long Budesonide and formoterol 320/9mcg INH Motivation required 320:9mcg acting Fenoterol 100mcg INH Berotec HFA Beta agonists , short acting Motivation required Fenoterol and ipratropium 200mcg INH Duovent HFA 200 dose Beta agonists , short acting Accepted treatment bromide Formoterol 12mcg CPS Foradil dry powder inhalation Foratec DP Caps Beta agonists, long acting Accepted treatment Formoterol 12mcg INH Foratec HFA Beta agonists, long acting Accepted treatment Ipratropium bromide 40mcg INH Ipvent anticholinergics Accepted treatment Ipratropium bromide 20mcg INH Atrovent anticholinergics Accepted treatment Salbutamol 100mcg INH Asthavent 200 dose Beta agonists , short acting Accepted treatment Asthavent 300d ecohaler cfc Salbutamol 100mcg INH Beta agonists , short acting Accepted treatment free Salbutamol 200mcg CAP Asthavent DP Ventodis ks(8 s) Beta agonists , short acting Accepted treatment Salbutamol 100mcg INH Venteze CFC free Beta agonists , short acting Accepted treatment Salbutamol 100mcg INH Venteze complete Beta agonists , short acting Accepted treatment Page 2 of 81 DOSAGE ACTIVE INGREDIENT STRENGTH EXAMPLE 1 EXAMPLE 2 CLASS COMMENT FORM Salbutamol 400mcg CPS Ventodisks(8 s) Beta agonists , short acting Motivation required Salbutamol 100mcg INH Ventolin inhaler 200 cfc-free Beta agonists , short acting Accepted treatment Salbutamol 2.5mg SLN Ventolin nebules Salbu-neb Beta agonists , short acting Motivation required Salbutamol and other drugs for INH Combivent Beta agonist & anticholinergic Accepted treatment obstructive airway diseases Salmeterol and fluticasone 25/125mcg INH Foxair Salmeterol and fluticasone Motivation required Corticosteroids and beta agonists, long Salmeterol and fluticasone 25/250mcg INH Foxair Motivation required acting Corticosteroids and beta agonists, long Salmeterol and fluticasone 25/50mcg INH Foxair Motivation required acting Corticosteroids and beta agonists, long Salmeterol and fluticasone 50/100mcg ACC Foxair Motivation required acting Corticosteroids and beta agonists, long Salmeterol and fluticasone 50/250mcg ACC Foxair Motivation required acting Corticosteroids and beta agonists, long Salmeterol and fluticasone 50/500mcg ACC Foxair Motivation required acting Corticosteroids and beta agonists, long Salmeterol and fluticasone 25mcg/125mcg INH Sereflo HFA 25/125 Dose 120 Motivation required acting Corticosteroids and beta agonists, long Salmeterol and fluticasone 25mcg/250mcg INH Sereflo HFA 25/250 Dose 120 Motivation required acting Corticosteroids and beta agonists, long Salmeterol and fluticasone 25mcg/50mcg INH Sereflo HFA 25/50 120 Dose Motivation required acting Corticosteroids and beta agonists, long Salmeterol and fluticasone 25mcg/125mcg INH Seretide 25/125 120 dose Motivation required acting Corticosteroids and beta agonists, long Salmeterol and fluticasone 25mcg/250mcg INH Seretide 25/250 120 dose Motivation required acting Corticosteroids and beta agonists, long Salmeterol and fluticasone 25mcg/50mcg INH Seretide 25/50 120 dose Motivation required acting Corticosteroids and beta agonists, long Salmeterol and fluticasone 100mcg INH Seretide accuhaler 50/100 Motivation required acting Corticosteroids and beta agonists, long Salmeterol and fluticasone 250mcg INH Seretide Accuhaler 50/250 Motivation required acting Corticosteroids and beta agonists, long Salmeterol and fluticasone 500mcg INH Seretide accuhaler 50/500 Motivation required acting Theophylline 250mg SRT Euphyllin retard Xanthines Motivation required Theophylline 125mg SRC Microphyllin Xanthines Motivation required Theophylline 250mg SRC Microphyllin Xanthines Motivation required Theophylline 250mg SRT Nuelin sa 250 Xanthines Motivation required Theophylline 300mg SRT Pulmophyllin sr 300 Xanthines Motivation required SANDOZ Theophyllin Theophylline 200mg SRT Xanthines Motivation required Anhydrous SR Page 3 of 81 DOSAGE ACTIVE INGREDIENT STRENGTH EXAMPLE 1 EXAMPLE 2 CLASS COMMENT FORM SANDOZ Theophyllin Theophylline 300mg SRT Xanthines Motivation required Anhydrous SR Theophylline 200mg SRT Theoplus Xanthines Motivation required Theophylline 300mg SRT Theoplus Xanthines Motivation required Theophylline 400mg SRT Uniphyl 400 Xanthines Motivation required Theophylline 600mg SRT Uniphyl 600 Xanthines Motivation required BIPOLAR MOOD DISORDER ICD10: F31.0, F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.8, F31.9 Amitriptyline 25mg TAB SANDOZ Amitryptyline Trepiline Heterocyclic antidepressant Accepted treatment Carbamazepine 200mg TAB CPL-Carbamazepine Degranol Mood Stabilisers Accepted treatment Carbamazepine 400mg SRT SANDOZ Cabamazepine CR Tegretol CR Mood Stabilisers Accepted treatment Carbamazepine 200mg SRT SANDOZ Carbamazepine CR Tegretol CR Mood Stabilisers Accepted treatment Chlorpromazine 100mg TAB Largactil Antipsychotics Motivation required Chlorpromazine 25mg TAB Largactil Antipsychotics Motivation required Chlorpromazine 50mg TAB Largactil Antipsychotics Motivation required Citalopram 20mg TAB Adco-Talomil Arrow Citalopram Selective serotonin receptor inhibitors Accepted treatment Citalopram 10mg TAB Austell-Citalopram Selective serotonin receptor inhibitors Accepted treatment Citalopram 40mg TAB DRL-Citalopram Ran-Citalopram Selective serotonin receptor inhibitors Accepted treatment Clomipramine 10mg TAB Equinorm Clomidep Heterocyclic antidepressants Accepted treatment Clomipramine 25mg TAB Equinorm Clomidep Heterocyclic antidepressants Accepted treatment Dosulepin 25mg CAP Prothiaden Thaden Heterocyclic antidepressants Accepted treatment Dosulepin 75mg TAB Thaden Selective serotonin receptor
Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Composition for Rectal Administration Combined with an Oral Alpha-Lipoic
    (19) & (11) EP 2 162 125 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/136 (2006.01) A61K 31/01 (2006.01) 19.10.2011 Bulletin 2011/42 A61P 1/00 (2006.01) A61K 45/06 (2006.01) A61K 31/56 (2006.01) A61K 31/573 (2006.01) (2006.01) (21) Application number: 08768441.1 A61K 31/606 (22) Date of filing: 13.06.2008 (86) International application number: PCT/US2008/007401 (87) International publication number: WO 2008/156671 (24.12.2008 Gazette 2008/52) (54) Composition for rectal administration combined with an oral alpha-lipoic acid composition for the treatment of inflammatory bowel disease Zusammensetzung zur rektalen Verabreichung kombiniert mit einer oralen Zusammentzung enthaltend alpha Liponsäure zur Behandlung von entzündlicher Darmerkrankung Composition pour l’administration rectale en combinaison avec une composition orale de l’ acide alpha- lipoique pour le traitment des maladies intestinales inflammatoires (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR EP-B1- 0 671 168 WO-A2-02/089796 HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT US-A- 4 657 900 US-A- 5 082 651 RO SE SI SK TR US-A- 5 378 470 (30) Priority: 13.06.2007 US 934505 P • MULDER CJ. ET AL.: ’Beclomethasone 06.02.2008 US 63745 P dipropionate (3mg) versus 5- aminosalicylic acid (2g) versus the combination of both (3mg/2g)as (43) Date of publication of application: retention enemas in active ulcerative proctitis’ 17.03.2010 Bulletin 2010/11 EUR.J.GASTROENTEROL HEPATOL vol.
    [Show full text]
  • Inhaled Corticosteroid (ICS) Only – Metered Dose Inhalers (MDI)
    Categorisation and Formulary Choices of Inhaled Corticosteroids for Adults Inhaled Corticosteroid (ICS) only – Metered Dose Inhalers (MDI) MDI Beclometasone dipropionate Use with a compatible Fluticasone Propionate spacer device Prescribe by BRAND Clenil Modulite® Qvar®(extrafine) Qvar®(extrafine) Flixotide® Evohaler MDI Easi-Breathe Low Dose 100mcg, two puffs twice a 50 mcg, two puffs twice a day 50 mcg, two puffs twice a day 50 mcg, two puffs twice a day (BDP equivalent day (200 dose) (200 dose) (200 dose) (120 dose) ≤400mcg BDP) £4.45/month £4.72/month £4.64/month £5.44/month Medium Dose 200mcg, two puffs twice a 100 mcg, two puffs twice a day 100 mcg, two puffs twice a day 125mcg, two puffs twice a day (BDP equivalent day (200 dose) (200 dose) (200 dose) (120 dose) 400-1000mcg BDP) £9.70/month £10.33/month £10.17/month £12.50/month High Dose 250mcg, two puffs twice a 100 mcg, four puffs twice a day 100 mcg, four puffs twice a day 250mcg, two puffs twice a day (BDP equivalent day (200 dose) (200 dose) (200 dose) (120 dose) >1000mcg BDP) £9.77/month £20.66/month £20.34/month £20.00/month Simultaneous specialist OR referral recommended 250mcg four puffs, twice a day (200 dose) £19.55/month Prices correct as per Drug Tariff and DM&D December2018 1st line choices (dark green, solid border) 2nd line choices (light green, dashed border) Approved by Hertfordshire Medicines Management Committee – October 2018 Inhaled Corticosteroid (ICS) only – Dry Powder Inhalers (DPI) Beclometasone DPI dipropionate Budesonide Fluticasone Propionate Prescribe
    [Show full text]
  • BSG Plan for IBD Patients During COVID19 Pandemic V1.5 349.88 KB
    British Society of Gastroenterology (BSG) advice for management of inflammatory bowel diseases during the COVID-19 pandemic Date of publication: 22nd March 2020 Introduction Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a condition in which the gastrointestinal immune system responds inappropriately. It is therefore often treated with immune suppression medications to control inflammation and to prevent ‘flares’, a worsening in symptoms, which may be unpredictable. It is known that 0.8% of people in the UK (approx. 524,000 patients) currently have IBD, but only 44% have been to a clinic in the last 3 years1,2. There will be many patients who will be worried about the effect of the Coronavirus pandemic (SARS-CoV-2 or COVID-19 disease) on their IBD and vice versa. During the COVID-19 outbreak we will do everything we can to keep our IBD patients safe. The biggest risks are related not only to the infection itself, but also the emergency reorganisation of hospital and general practice services to deal with the pandemic, meaning routine IBD services will be significantly affected. A combined approach covering both primary and secondary care is therefore required to keep vulnerable IBD patients out of hospital as much as possible. Insights from Hubei, China and from Italy suggest hospital admission for non-COVID-19 illness will provide a reservoir for further spread of infection. However, alterations to the way we deliver IBD care in the UK must be balanced against the risks of undertreated, active IBD. Importantly, patients with active IBD are likely to have a higher risk of infection both in the community and during inpatient care, even in the absence of immunosupressant treatment3.
    [Show full text]
  • FF/UMEC/VI) Triple Therapy Versus Tiotropium Monotherapy in Patients with COPD
    www.nature.com/npjpcrm ARTICLE OPEN Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD Sandeep Bansal1, Martin Anderson2, Antonio Anzueto3,4, Nicola Brown5, Chris Compton6, Thomas C. Corbridge7,8, David Erb9, Catherine Harvey5, Morrys C. Kaisermann10, Mitchell Kaye11, David A. Lipson 10,12, Neil Martin6,13, Chang-Qing Zhu5 and ✉ Alberto Papi 14 Chronic obstructive pulmonary disease (COPD) treatment guidelines do not currently include recommendations for escalation directly from monotherapy to triple therapy. This 12-week, double-blind, double-dummy study randomized 800 symptomatic moderate-to-very-severe COPD patients receiving tiotropium (TIO) for ≥3 months to once-daily fluticasone furoate/umeclidinium/ vilanterol (FF/UMEC/VI) 100/62.5/25 mcg via ELLIPTA (n = 400) or TIO 18 mcg via HandiHaler (n = 400) plus matched placebo. Study endpoints included change from baseline in trough forced expiratory volume in 1 s (FEV1) at Days 85 (primary), 28 and 84 (secondary), health status (St George’s Respiratory Questionnaire [SGRQ] and COPD Assessment Test [CAT]) and safety. FF/UMEC/VI significantly improved trough FEV1 at all timepoints (Day 85 treatment difference [95% CI] 95 mL [62–128]; P < 0.001), and significantly improved SGRQ and CAT versus TIO. Treatment safety profiles were similar. Once-daily single-inhaler FF/UMEC/VI significantly improved lung function and health status versus once-daily TIO in symptomatic moderate-to-very-severe COPD 1234567890():,; patients, with a similar safety profile. npj Primary Care Respiratory Medicine (2021) 31:29 ; https://doi.org/10.1038/s41533-021-00241-z INTRODUCTION performed to date and a lack of updated recommendations Chronic obstructive pulmonary disease (COPD) is a major cause of based on the current body of evidence.
    [Show full text]
  • A Practical Approach To, Diagnosis, Assessment and Management Of
    REVIEW A practical approach to, diagnosis, Pract Neurol: first published as 10.1136/practneurol-2014-000821 on 8 May 2014. Downloaded from assessment and management of idiopathic intracranial hypertension Susan P Mollan,1 Keira A Markey,2 James D Benzimra,1 Andrew Jacks,1 Tim D Matthews,1 Michael A Burdon,1 Alex J Sinclair2,3 1Birmingham Neuro- ABSTRACT term to encompass primary raised intra- Ophthalmology Unit, Adult patients who present with papilloedema cranial pressure where there is no identi- Ophthalmology Department, — — University Hospitals Birmingham and symptoms of raised intracranial pressure fiable cause which we term IIH and 3 NHS Trust, Queen Elizabeth need urgent multidisciplinary assessment secondary causes of raised pressure. Hospital Birmingham, including neuroimaging, to exclude life- The diagnostic criteria of IIH are well Birmingham, UK 2 threatening causes. Where there is no apparent known and have evolved since Dandy’s Neurotrauma and 4 Neurodegeneration, School of underlying cause for the raised intracranial initial description in 1937 ; they include Clinical and Experimental pressure, patients are considered to have a CSF opening pressure of ≥25 cm H2O Medicine, College of Medical idiopathic intracranial hypertension (IIH). The (box 1).3 However, these criteria recom- and Dental Sciences, The incidence of IIH is increasing in line with the mend imaging only to exclude a venous Medical School, The University of Birmingham, Birmingham, UK global epidemic of obesity. There are sinus thrombosis in patients without the 3Department of Neurology, controversial issues in its diagnosis and typical IIH phenotype (obesity and University Hospital Birmingham management. This paper gives a practical female sex). We feel, however, that it is NHS Trust, Queen Elizabeth Hospital Birmingham, approach to assessing patients with essential to exclude venous sinus throm- Birmingham, UK papilloedema, its investigation and the bosis (using MRI or CT with venography) subsequent management of patients with IIH.
    [Show full text]
  • Utah Medicaid Pharmacy and Therapeutics Committee Drug
    Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review Single Ingredient Nasal Corticosteroids Beclomethasone dipropionate (Qnasl) Beclomethasone dipropionate monohydrate (Beconase AQ) Budesonide (Rhinocort) Ciclesonide (Omnaris, Zetonna) Flunisolide (Generic) Fluticasone Furoate (Flonase Sensimist) Fluticasone Propionate (Flonase, Xhance) Mometasone Furoate (Nasonex) Triamcinolone Acetonide (Nasacort) AHFS Classification: 52.08.08 Corticosteroids (EENT) Final Report February 2018 Review prepared by: Valerie Gonzales, Pharm.D., Clinical Pharmacist Elena Martinez Alonso, B.Pharm., MSc MTSI, Medical Writer Vicki Frydrych, Pharm.D., Clinical Pharmacist Joanita Lake, B.Pharm., MSc EBHC (Oxon), Research Assistant Professor Joanne LaFleur, Pharm.D., MSPH, Associate Professor University of Utah College of Pharmacy University of Utah College of Pharmacy, Drug Regimen Review Center Copyright © 2018 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved Contents Abbreviations ................................................................................................................................................ 2 Executive Summary ....................................................................................................................................... 3 Introduction .................................................................................................................................................. 5 Table 1. Nasal corticosteroid products .............................................................................................
    [Show full text]
  • Pharmacology/Therapeutics II Block III Lectures 2013-14
    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
    [Show full text]
  • QVAR™ (BECLOMETASONE DIPROPIONATE) AUTOHALER™ and QVAR™ (BECLOMETASONE DIPROPIONATE) INHALER 1 NAME of the MEDICINE Beclometasone Dipropionate
    AUSTRALIAN PRODUCT INFORMATION – QVAR™ (BECLOMETASONE DIPROPIONATE) AUTOHALER™ and QVAR™ (BECLOMETASONE DIPROPIONATE) INHALER 1 NAME OF THE MEDICINE Beclometasone dipropionate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Beclometasone dipropionate (BDP) is a white to creamy white, odourless powder; it is slightly soluble in water, very soluble in chloroform and freely soluble in acetone and alcohol. QVAR also contains ethanol and norflurane (HFA-134a), a propellant which does not contain chlorofluorocarbons (CFCs). Excipients with known effects: ethanol (alcohol) 11.85 % v/v. QVAR 50 Inhaler and Autohaler deliver 50 µg of BDP per inhalation. QVAR 100 Inhaler and Autohaler deliver 100 µg of BDP per inhalation. QVAR Autohaler is a breath actuated inhaler which automatically releases a metered dose of medication during inhalation through the mouthpiece and overcomes the need for patients to coordinate actuation with inspiration. QVAR Inhaler is a conventional press and breathe metered dose inhaler (P&B MDI). There are no differences in formulation between the Autohaler and the Inhaler products. QVAR contains BDP in solution, resulting in an extra fine aerosol. The aerosol droplets of QVAR are on average much smaller (Mass Median Aerodynamic Diameter (MMAD), MMAD range 0.8 to 1.2 microns) than the particle sizes delivered by CFC-suspension formulations (MMAD range 3.5 to 4 microns) or dry powder formulations (MMAD approximately 10 microns) of BDP. The smaller particle size for QVAR results in greater deposition in the airways and less deposition in the oropharynx than beclometasone products formulated in CFCs. Radiolabelled deposition studies demonstrated that for QVAR the majority of BDP (>55 % dose ex actuator) is deposited in the lungs and a small amount (< 35 % dose ex actuator) is deposited in the oropharynx.
    [Show full text]
  • Identification and Validation of Novel Hpxr Activators Amongst
    DMD Fast Forward. Published on November 10, 2010 as DOI: 10.1124/dmd.110.035808 DMD FastThis Forward. article has not Published been copyedited on andNovember formatted. The 10, final 2010 version as maydoi:10.1124/dmd.110.035808 differ from this version. DMD #35808 Identification and Validation of Novel hPXR Activators Amongst Prescribed Drugs via Ligand-Based Virtual Screening Yongmei Pan, Linhao Li, Gregory Kim, Sean Ekins, Hongbing Wang and Peter W. Swaan Downloaded from Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, 20 Penn Street, Baltimore, MD 21201, USA; Collaborations in Chemistry, Jenkintown, PA 19046, USA (SE); Department of Pharmacology, University of Medicine & Dentistry dmd.aspetjournals.org of New Jersey (UMDNJ)-Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA (SE). at ASPET Journals on September 24, 2021 1 Copyright 2010 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on November 10, 2010 as DOI: 10.1124/dmd.110.035808 This article has not been copyedited and formatted. The final version may differ from this version. DMD #35808 a) Running Title: Identification of Novel hPXR Activators b) Corresponding Author: Peter W. Swaan, Ph.D., Department of Pharmaceutical Sciences, University of Maryland, 20 Penn Street, HSF2-621, Baltimore, MD 21201 USA Tel: (410) 706-0103 Fax: (410) 706-5017 Email: [email protected] Downloaded from c) Number of: Text pages: 35 dmd.aspetjournals.org Tables: 3 Figures: 6 References: 45 at ASPET Journals on September 24, 2021 Words in Abstract: 196 Words in Introduction: 546 Words in Discussion: 1,521 d) Abbreviations: hPXR, Human pregnane X receptor; LBD, ligand binding domain; XV ROC AUC, Leave-one-out cross-validation based ‘receiver operator curve’ area under the curve.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Beclometasone for Asthma
    information for parents and carersrs Beclometasone inhaler for asthma prevention (prophylaxis) This leafl et is about the use of inhaled beclometasone for asthma. It is taken regularly in order to prevent attacks. (This is sometimes called asthma prophylaxis.) This leafl et has been written for parents and carers about how The dose will be shown on the medicine label. to use this medicine in children. Our information sometimes It is important that you follow your doctor’s differs from that provided by the manufacturers, because their instructions about how much to give. information is usually aimed at adult patients. Please read this leafl et carefully. Keep it somewhere safe so that you can How should I give beclometasone? read it again. Your doctor or asthma nurse will show you how to use the aerosol inhaler and spacer device. Beclometasone inhalers should not be used during Detailed information on how to use the inhalers is given an acute asthma attack (sudden onset of wheezing on the last page of this leafl et. and breathlessness). Use your child’s reliever medicine (usually in a blue salbutamol inhaler). When should the medicine start working? Beclometasone needs to be given regularly to prevent Name of drug asthma and wheeze. Your child should start to wheeze less, Beclometasone dipropionate (often known as and to need less reliever medicine, 3–7 days after starting beclometasone for short) treatment. Continue to give the medicine, as told to by your It comes in a variety of different aerosol and dry powder doctor or nurse, even if your child does not have any wheeze inhalers, which have different brand names.
    [Show full text]